2. Search Result
Search Result
Results for "

gastrointestinal+tract

" in MedChemExpress (MCE) Product Catalog:

72

Inhibitors & Agonists

1

Biochemical Assay Reagents

5

Peptides

5

Natural
Products

9

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Nom du produit Target Áreas de investigación Chemical Structure
  • HY-B2196
    Gastric mucin
    3 Publications Verification

    		 Antibiotic Bacterial Infection Metabolic Disease
    Gastric mucin is a glycoprotein with natural antibiotic function. Gastric mucin against Helicobacter pylori infection. Gastric mucin effectively scavenges hydroxyl radical. Gastric mucin play a major role in the protection of the gastrointestinal tract from acid, proteases, pathogenic microorganisms, and mechanical trauma .
    Gastric mucin
  • HY-N1425
    Tiliroside
    3 Publications Verification

    		 Others Metabolic Disease
    Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of α-amylase with a Ki value of 84.2  μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .
    Tiliroside
  • HY-126373
    SN-38 glucuronide

    SN-38G

    		 Drug Metabolite Cancer
    SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .
    SN-38 glucuronide
  • HY-109519
    Simethicone

    		Environmental Pollutants Biochemical Assay Reagents Others Cancer
    Simethicone is an orally active defoamer. Simethicone reduces the surface tension of air bubbles in the gastrointestinal tract, causing them to be expelled by vomiting, exhalation or absorption into the bloodstream. Simethicone has potential applications in flatulence and colic .
    Simethicone
  • HY-111613
    Pinaverium bromide
    4 Publications Verification

    		 Calcium Channel Cancer
    Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients .
    Pinaverium bromide
  • HY-14739
    Choline Fenofibrate
    3 Publications Verification

    ABT-335

    		 PPAR COX Cardiovascular Disease
    Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect .
    Choline Fenofibrate
  • HY-13831
    BPTU
    1 Publications Verification

    BMS-646786

    		 P2Y Receptor Neurological Disease Cancer
    BPTU (BMS-646786) is a non-nucleotide P2Y1 receptor allosteric antagonist with antithrombotic activity. BPTU is able to block the P2Y1 receptor located at the neuromuscular junction of the gastrointestinal tract .
    BPTU
  • HY-B1339
    Dicyclomine hydrochloride

    Dicycloverine hydrochloride

    		 mAChR Neurological Disease
    Dicyclomine hydrochloride is a potent and orally active muscarinic cholinergic receptors antagonist. Dicyclomine hydrochloride shows high affinity for muscarinic M1 receptor subtype (Ki=5.1 nM) and M2 receptor subtype (Ki=54.6 nM) in brush-border membrane and basal plasma membranes, respectively . Dicyclomine is an antispasmodic agent and relieves smooth muscle spasm of the gastrointestinal tract in vivo .
    Dicyclomine hydrochloride
  • HY-A0118A
    Naloxegol oxalate
    2 Publications Verification

    NKTR-118 oxalate; AZ-13337019 oxalate

    		 Opioid Receptor Metabolic Disease
    Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is an orally active peripherally acting μ-opioid receptor antagonist with a target Ki of 7.42 nM. Naloxegol oxalate inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol oxalate is applicable to research related to opioid-induced constipation .
    Naloxegol oxalate
  • HY-13995A
    Sevelamer hydrochloride
    1 Publications Verification

    		 FXR Metabolic Disease Endocrinology
    Sevelamer hydrochloride is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer hydrochloride binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer hydrochloride binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer hydrochloride can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes .
    Sevelamer hydrochloride
  • HY-125159
    Derquantel

    PF-00520904

    		 Parasite nAChR Infection
    Derquantel, a spirocyclic anthelmintic, is a competitive, orally active nicotinic acetylcholine receptor (nAChR) antagonist. Derquantel inhibits ACh-induced depolarization with an IC50 of 0.22 μM. By selectively antagonizing nAChRs on the somatic muscles of nematodes, Derquantel causes flaccid paralysis of muscles, thereby dislodging parasites from the host's gastrointestinal tract. Derquantel is applicable to research related to Haemonchus contortus infection and Ascaris suum infection .
    Derquantel
  • HY-13995B
    Sevelamer carbonate
    1 Publications Verification

    		 FXR Metabolic Disease Endocrinology
    Sevelamer carbonate is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer carbonate binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer carbonate binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer carbonate can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes .
    Sevelamer carbonate
  • HY-106539
    Colesevelam hydrochloride

    		FXR G protein-coupled Bile Acid Receptor 1 GLP Receptor Metabolic Disease Cancer
    Colesevelam hydrochloride is an orally active bile acid sequestrant, lipid-lowering agent, and glycemic control agent. Colesevelam hydrochloride binds bile acids in the gastrointestinal tract to form nonabsorbable complexes, interrupts enterohepatic recirculation and increases fecal bile acid elimination. Colesevelam hydrochloride modulates FXR, TGR5, and Cyp7a1 activity and triggers cAMP signaling and GLP-1 release. Colesevelam hydrochloride alters hepatic lipid and glucose metabolism, suppresses hepatic glycogenolysis, reduces hepatic triglyceride and cholesterol levels, and increases LDL-C (low-density lipoprotein cholesterol) clearance. Colesevelam hydrochloride can be used for the research of type 2 diabetes mellitus, hypercholesterolemia, and alcohol-related liver disease .
    Colesevelam hydrochloride
  • HY-118189
    Misoprostol acid
    1 Publications Verification

    		 Prostaglandin Receptor Inflammation/Immunology
    Misoprostol acid is an active metabolite of Misoprostol. Misoprostol is a synthetic analogue of prostaglandin E1 (PGE1), extensively absorbed, and undergoes rapid de-esterification to Misoprostol acid in the gastrointestinal tract after oral administration. Misoprostol can be used for non-steroidal anti-inflammatory drug-induced (NSAID) gastric ulcers . Misoprostol is an oral agent used to induce labor .
    Misoprostol acid
  • HY-N15135
    Arabinoxylan (Medium viscosity)

    		Interleukin Related Toll-like Receptor (TLR) Fungal Metabolic Disease
    Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome .
    Arabinoxylan (Medium viscosity)
  • HY-116016
    Etilevodopa

    L-DOPA ethyl ester; Levodopa ethyl ester

    		 Dopamine Receptor Drug Metabolite Neurological Disease
    Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .
    Etilevodopa
  • HY-B1048
    Pasiniazid

    Paraniazide; Pasiniazide; Isonicotinic acid hydrazide p-aminosalicylate

    		 Bacterial Infection
    Pasiniazid is a chemical complex formed by Isoniazid (HY-B0329) and Para-aminosalicylic acid in a 1:1 molar ratio. Pasiniazid is an antibacterial agent. Pasiniazid is rapidly decomposed into isoniazid and para-aminosalicylic acid in the gastrointestinal tract. Isoniazid exerts a bactericidal effect, while para-aminosalicylic acid delays the acetylation process of isoniazid. Pasiniazid has antibacterial activity against Mycobacterium tuberculosis. Pasiniazid can be used in tuberculosis research .
    Pasiniazid
  • HY-119972
    Diloxanide

    		Parasite Infection
    Diloxanide is an anti-protozoal agent and can be used for the research of asymptomatic-intestinal amebiasis caused by Entamoeba histolytica or some other protozoal infections. Diloxanide is an active luminal amebicide and hydrolyzed in the gastrointestinal tract from its proagent Diloxanide furoate (HY-B1147) .
    Diloxanide
  • HY-144034
    GLP-1R agonist 3

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 3 is a potent agonist of GLP-1R. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1) .
    GLP-1R agonist 3
  • HY-B1390A
    Saccharin sodium

    		Environmental Pollutants Bacterial Infection
    Saccharin sodium is an orally active, non-caloric artificial sweetener (NAS). Saccharin sodium has bacteriostatic and microbiome-modulating properties. Saccharin binds to and signals via specific taste receptors, not only in the oral cavity but also alongside the gastrointestinal tract. Saccharin has been reported to bind the human and rodent heteromeric guanine nucleotide-binding protein (G protein) coupled sweet taste receptors T1R2/T2R3 as well as the human bitter taste receptor T2R43 and T2R44. Saccharin can inhibit bacterial growth in vitro .
    Saccharin sodium
  • HY-P3021
    Human milk lysozyme
    2 Publications Verification

    		 Bacterial Biochemical Assay Reagents Infection
    Human milk lysozyme is the lysozyme found in human milk. Human milk lysozyme is thought to be a key defense factor in protecting the gastrointestinal tract of newborns against bacterial infection .
    Human milk lysozyme
  • HY-108283
    Trepibutone

    AA 149; Supacal

    		 Calcium Channel Inflammation/Immunology
    Trepibutone (AA 149) increases secretion of bile and pancreatic juice, and accelerates flaccidity of the smooth muscle in the gastrointestinal tract. Trepibutone can be used for the research of cholecystitis and functional gastrointestinal disorders .
    Trepibutone
  • HY-P1179
    Guanylin(human)

    		Guanylate Cyclase Endogenous Metabolite Endocrinology Cancer
    Guanylin(human), a 15-amino acid peptide, is an endogenous intestinal guanylate cyclase activator. Guanylin(human) is mainly found in gastrointestinal tract which regulates electrolytead water transport in intestinal and renal epithelia through cyclic GMP-dependent mechanism .
    Guanylin(human)
  • HY-P1179A
    Guanylin(human) TFA

    		Guanylate Cyclase Endogenous Metabolite Metabolic Disease
    Guanylin(human) TFA, a 15-amino acid peptide, is an endogenous intestinal guanylate cyclase activator. Guanylin(human) TFA is mainly found in gastrointestinal tract which regulates electrolytead water transport in intestinal and renal epithelia through cyclic GMP-dependent mechanism .
    Guanylin(human) TFA
  • HY-N7665
    Prosaikogenin G

    		Others Metabolic Disease
    Prosaikogenin G, isolated from the roots of Bupleurum chinensis DC., exhibits significant inhibitory effects on rat mesangial cell proliferation induced by Ang II. Prosaikogenin G has protective action on the kidney . Prosaikogenin G is a derivative of Saikosaponin d in the gastrointestinal tract .
    Prosaikogenin G
  • HY-B1806A
    Tridihexethyl chloride

    Pathilon chloride

    		 mAChR Neurological Disease Inflammation/Immunology
    Tridihexethyl (Pathilon) chloride is an orally active anticholinergic agent and mAChR antagonist, shows activities of antimuscarinic and anticholinergic. Tridihexethyl chloride shows pronounced antispasmodic and antisecretory effects on the gastrointestinal tract. Tridihexethyl chloride can be used in studies of peptic ulcer disease and acquired nystagmus .
    Tridihexethyl chloride
  • HY-144035
    GLP-1R agonist 4

    		GCGR Metabolic Disease Inflammation/Immunology
    GLP-1R agonist 4 is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 can be used for the research of type 2 diabetes mellitus, obesity, non-alcoholic steatohepatitis, insulin resistance and etc .
    GLP-1R agonist 4
  • HY-101014
    Octanoylcarnitine chloride

    		Biochemical Assay Reagents Infection
    Octanoylcarnitine chloride is a homolog of acetylcarnitine chloride. Octanoylcarnitine chloride can enhance absorption of drugs from gastrointestinal tract .
    Octanoylcarnitine chloride
  • HY-P2793
    Uperolein

    		Neurokinin Receptor Neurological Disease
    Uperolein is a physalaemin-like endecapeptide, produced in the skin of Uperoleia rugosa and Uperoleia marmorata. Uperolein has a spasmodic effect on both the gastrointestinal tract and longitudinal muscles .
    Uperolein
  • HY-106525
    Aclatonium napadisylate

    		Cholinesterase (ChE) Inflammation/Immunology
    Aclatonium napadisylate is a cholinergic agonist. Aclatonium napadisylate can increase amylase release and Ca 2+ efflux. Aclatonium napadisylate can stimulate pancreatic exocrine secretion and increase motility and peristalsis of the gastrointestinal tract. Aclatonium napadisylate can be used for the research of gastrointestinal disorders .
    Aclatonium napadisylate
  • HY-116016A
    Etilevodopa hydrochloride

    L-DOPA ethyl ester hydrochloride; Levodopa ethyl ester hydrochloride

    		 Dopamine Receptor Drug Metabolite Neurological Disease
    Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .
    Etilevodopa hydrochloride
  • HY-176838
    LXT34

    		Free Fatty Acid Receptor GLP Receptor Inflammation/Immunology
    LXT34 (Example 2) is a GPR120 agonist. LXT34 has an anti-inflammatory activity. LXT34 promotes GLP-1 formation in the gastrointestinal tract and improves insulin resistance in macrophages and pancreas cells. LXT34 can be used for inflammatory diseases, such as type 2 diabetes, obesity and non-alcoholic fatty liver research .
    LXT34
  • HY-13995
    Sevelamer

    		FXR Metabolic Disease Endocrinology
    Sevelamer is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes .
    Sevelamer
  • HY-G0008A
    O-Desmethyl Mebeverine alcohol hydrochloride

    Mebeverine metabolite O-desmethyl Mebeverine alcohol hydrochloride

    		 Adrenergic Receptor Drug Metabolite Metabolic Disease
    O-Desmethyl Mebeverine alcohol hydrochloride is a metabolite of Mebeverine, which is a potent α1 repector inhibitor, causing relaxation of the gastrointestinal tract.
    O-Desmethyl Mebeverine alcohol hydrochloride
  • HY-G0008
    O-Desmethyl Mebeverine alcohol

    Mebeverine metabolite O-desmethyl Mebeverine alcohol

    		 Adrenergic Receptor Drug Metabolite Metabolic Disease
    O-Desmethyl Mebeverine alcohol is a metabolite of Mebeverine, which is a potent α1 repector inhibitor, causing relaxation of the gastrointestinal tract.
    O-Desmethyl Mebeverine alcohol
  • HY-105263
    EM574

    		Motilin Receptor Metabolic Disease
    EM574 is a potent motilin receptor agonist in the human gastric antrum and rabbit gastrointestinal tract in vitro. EM574 is an erythromycin derivative .
    EM574
  • HY-P2636
    Cholecystokinin Precursor (24-32) (rat)

    Prepro CCK Fragment V-9-M

    		 Histamine Receptor Metabolic Disease
    Cholecystokinin Precursor (24-32) (rat) is a cholecystokinin precursor that can be expressed in the heart, lungs, and kidneys as well as in the gastrointestinal tract and brain. Cholecystokinin is a brain-gut peptide that stimulates gallbladder contraction and pancreatic exocrine secretion and also acts as a neurotransmitter .
    Cholecystokinin Precursor (24-32) (rat)
  • HY-111613S
    Pinaverium bromide-d4

    		Isotope-Labeled Compounds Calcium Channel Others
    Pinaverium bromide-d4 is deuterium labeled Pinaverium bromide. Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients .
    Pinaverium bromide-d4
  • HY-14149A
    Cisapride monohydrate
    2 Publications Verification

    R 51619 monohydrate; (±)-Cisaprid monohydrate

    		 5-HT Receptor Neurological Disease Metabolic Disease
    Cisapride monohydrate is an orally and potent 5-HT4 receptor agonist and hERG inhibitor. Cisapride monohydrate is an prokinetic agent which facilitates or restores motility throughout the length of the gastrointestinal tract. Cisapride monohydrate stimulates gastrointestinal motor activity through an indirect mechanism involving the release of acetylcholine mediated by postganglionic nerve endings in the myenteric plexus of the gut .
    Cisapride monohydrate
  • HY-111613R
    Pinaverium bromide (Standard)

    		Reference Standards Calcium Channel Cancer
    Pinaverium bromide (Standard) is the analytical standard of Pinaverium bromide. This product is intended for research and analytical applications. Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients .
    Pinaverium bromide (Standard)
  • HY-A0118
    Naloxegol

    NKTR-118; AZ-13337019

    		 Opioid Receptor Neurological Disease Cancer
    Naloxegol (NKTR-118; AZ-13337019) is an orally active peripherally acting μ-opioid receptor antagonist with a target Ki of 7.42 nM. Naloxegol inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol is applicable to research related to opioid-induced constipation .
    Naloxegol
  • HY-B1339A
    Dicyclomine

    Dicycloverine

    		 mAChR Neurological Disease
    Dicyclomine (Dicycloverine) is a potent and orally active muscarinic cholinergic receptors antagonist. Dicyclomine (Dicycloverine) shows high affinity for muscarinic M1 receptor subtype (Ki=5.1 nM) and M2 receptor subtype (Ki=54.6 nM) in brush-border membrane and basal plasma membranes, respectively . Dicyclomine is an antispasmodic agent and relieves smooth muscle spasm of the gastrointestinal tract in vivo .
    Dicyclomine
  • HY-144033
    GLP-1R agonist 1

    		GCGR Metabolic Disease
    GLP-1R agonist 1 is a potent agonist of GLP-1R. GLP-1R agonist 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 1 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 4) .
    GLP-1R agonist 1
  • HY-401721
    5-CNAC

    		Biochemical Assay Reagents Others
    5-CNAC is an orally active enhancer of absorption, with no pharmacological activity on its own. 5-CNAC can significantly enhance the absorption efficiency of the drug (such as Salmon calcitonin (HY-P0090)) when administered together with it in the gastrointestinal tract. 5-CNAC binds reversibly and non-covalently to peptide drugs, protecting them from degradation by gastrointestinal enzymes, increasing their lipid solubility, promoting passive transcellular absorption, and not damaging the integrity of the intestinal epithelium. 5-CNAC can be used in the research of adjuvants for orally administered peptide agents .
    5-CNAC
  • HY-B1390AR
    Saccharin sodium (Standard)

    		Bacterial Reference Standards Infection
    Saccharin (sodium) (Standard) is the analytical standard of Saccharin (sodium). This product is intended for research and analytical applications. Saccharin sodium is an orally active, non-caloric artificial sweetener (NAS). Saccharin sodium has bacteriostatic and microbiome-modulating properties. Saccharin binds to and signals via specific taste receptors, not only in the oral cavity but also alongside the gastrointestinal tract. Saccharin has been reported to bind the human and rodent heteromeric guanine nucleotide-binding protein (G protein) coupled sweet taste receptors T1R2/T2R3 as well as the human bitter taste receptor T2R43 and T2R44. Saccharin can inhibit bacterial growth in vitro .
    Saccharin sodium (Standard)
  • HY-W060417
    iST2-1

    		Interleukin Related Inflammation/Immunology Cancer
    iST2-1 is an Stimulation-2 (ST2) inhibitor with an IC50 value of 46.65 μM, blocks interaction between ST2 and IL-33, inhibits downstream signaling. iST2-1 functions as an immunomodulator, reduces proliferation of CD4 + and CD8 + T cells, increases regulatory T cell populations, reduces IFN-γ +CD4 + T cell populations, increases Foxp3 +CD4 + regulatory T cell populations in the gastrointestinal tract. iST2-1 reduces plasma soluble ST2 and IFN-γ levels, reduces graft-versus-host disease scores, improves survival in graft-versus-host disease animal models, preserves graft-versus-tumor effect. iST2-1 can be used for the research of graft-versus-host disease .
    iST2-1
  • HY-101744
    Ipsalazide

    		Autophagy Inflammation/Immunology
    Ipsalazide is a novel sulfasalazine analog designed to release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract.
    Ipsalazide
  • HY-164370
    Hesperidin dihydrochalcone

    		Bacterial Infection
    Hesperidin dihydrochalcone is a non-toxic, high-sweetness, low-calorie sweetener. Hesperidin dihydrochalcone has many biological activities such as anti-oxidation, protection of liver and kidney, bacteriostasis and improvement of gastrointestinal tract .
    Hesperidin dihydrochalcone
  • HY-N2304A
    Methyl-6-alpha-Naltrexol

    		Opioid Receptor Inflammation/Immunology
    Methyl-6-alpha-Naltrexol is a metabolite of Methylnaltrexone (MNTX). Methylnaltrexone is a selective mu-opioid receptor antagonist and functions as a peripherally acting receptor antagonist in tissues of the gastrointestinal tract .
    Methyl-6-alpha-Naltrexol
  • HY-122133
    CI 750

    		Others Metabolic Disease
    CI 750 is a potent and orally active antidiarrheal agent. CI 750 increases the motor pattern of the gastrointestinal tract. CI 750 shows a constipating activity. CI 750 shows no analgesic, addiction liability, or anticholinergic pharmacological activity .
    CI 750

Demande en ligne

Your information is safe with us. * Required Fields.

Civilité

  

Country or Region *

Nom du demandeur *

 

Nom de l'organisation *

Department *

     

Adresse e-mail *

 

Nom du produit *

Cat. No.

  

Requested quantity *

Numéro de téléphone *

     

Remarques

Demande en ligne

Inquiry Information

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent: